Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy
Open Access
- 23 April 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
Abstract
Over 55,000 people in the United States are diagnosed with pancreatic ductal adenocarcinoma (PDAC) yearly, and fewer than 20% of these patients survive a year beyond diagnosis. Chemotherapies are considered or used in nearly every PDAC case, but there is limited understanding of the complex signaling responses underlying resistance to these common treatments. Here, we take an unbiased approach to study protein kinase network changes following chemotherapies in patient-derived xenograft (PDX) models of PDAC to facilitate design of rational drug combinations. Proteomics profiling following chemotherapy regimens reveals that activation of JNK-JUN signaling occurs after 5-fluorouracil plus leucovorin (5-FU + LEU) and FOLFOX (5-FU + LEU plus oxaliplatin [OX]), but not after OX alone or gemcitabine. Cell and tumor growth assays with the irreversible inhibitor JNK-IN-8 and genetic manipulations demonstrate that JNK and JUN each contribute to chemoresistance and cancer cell survival after FOLFOX. Active JNK1 and JUN are specifically implicated in these effects, and synergy with JNK-IN-8 is linked to FOLFOX-mediated JUN activation, cell cycle dysregulation, and DNA damage response. This study highlights the potential for JNK-IN-8 as a biological tool and potential combination therapy with FOLFOX in PDAC and reinforces the need to tailor treatment to functional characteristics of individual tumors.Funding Information
- NIH Office of the Director (R01-CA193650)
- NIH Office of the Director (R01-CA199064)
- NIH Office of the Director (5-F30-CA213916)
This publication has 72 references indexed in Scilit:
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast CancerCell, 2012
- Discovery of Potent and Selective Covalent Inhibitors of JNKCell Chemical Biology, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Molecular signatures database (MSigDB) 3.0Bioinformatics, 2011
- Development of JNK2-Selective Peptide Inhibitors That Inhibit Breast Cancer Cell MigrationACS Chemical Biology, 2011
- Cross-talk between the p38α and JNK MAPK Pathways Mediated by MAP Kinase Phosphatase-1 Determines Cellular Sensitivity to UV RadiationPublished by Elsevier BV ,2010
- SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibitionOncogene, 2010
- Osmotic Stress Activates the TAK1-JNK Pathway While Blocking TAK1-mediated NF-κB Activation: TAO2 REGULATES TAK1 PATHWAYSPublished by Elsevier BV ,2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- AP-1 in cell proliferation and survivalOncogene, 2001